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Review  article
 There are very scant data on the epidemiology of primary 
immunodeficiency diseases (PIDs) in Korea. Here we attempted 
to estimate the PID epidemiology and disease burden in Korea. 
A systematic review was performed of studies retrieved from the 
PubMed, KoreaMed, and Google Scholar databases. Studies on 
PIDs published in Korean or English between January 2001 and 
November 2018 were analyzed. The number of PID patients 
and the healthcare costs were estimated from Health Insurance 
Review and Assessment Service (HIRA) Korea data for 2017. 
A total of 398 PID patients were identified from 101 reports. 
Immunodeficiencies affecting cellular and humoral immunity 
were reported in 11 patients, combined immunodeficiency 
with associated or syndromic features in 40, predominantly 
antibody deficiencies in 144, diseases of immune dysregulation 
in 58, congenital defects of phagocytes in 104, defects in the 
intrinsic and innate immunity in 1, auto-inflammatory disorders 
in 4, complement deficiencies in 36, and phenocopies of PID 
in none. From the HIRA reimbursement data, a total of 1,162 
outpatients and 306 inpatients were treated for 8,166 and 6,149 
days, respectively. In addition, reimbursement was requested 
for 8,200 outpatient and 1,090 inpatient cases and $1,924,000 
and $4,715,000 were reimbursed in 2017, respectively. This 
study systematically reviewed published studies on PID and 
analyzed the national open data system of the HIRA to estimate 
the disease burden of PID, for the first time in Korea.
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Key message
In this article, a systematic review of reported primary immu-
nodeficiency disease (PID) cases in Korea was performed 
and we attempted to estimate the number of PID patients and 
healthcare costs for the first time in Korea. Our review revealed 
that Korean PID cases are greatly underreported in the literature 
based on health insurance. Physicians in the field and health care 
policymakers should be aware of the disease burden of PID.
Introduction
Primary immunodeficiency diseases (PIDs) are inborn errors 
of immunity caused by a single-gene mutation. Almost 300 PIDs 
have been identified to date, and more continue to be discovered. 
Patients with PID are known to have increased susceptibility 
to infection caused by usual or unusual pathogens. However, 
phenotypes of PID are diverse with additional features such as 
malignancy, allergy, autoimmunity, and autoinflammation.
Global and national epidemiology of PIDs
PIDs are considered rare diseases. However, with recent 
advances in diagnostics, increased awareness, improved care 
quality, and registry projects in many countries and continents, the 
number of identified PID patients is increasing. There are several 
well-established PID patient registries in America, Africa, and 
Europe (Table 1).1-3) There is a movement for the development of 
a PID registry in the Asia-Pacific region, and Japan already has a 
well-established PID registry (Table 1).4)
Growing evidence suggests that PID might be more common 
than generally thought. A study from 2013 estimated that, al-
though there are as many as 6 million people with PID, less than 
1% have been identified.1) There have been many attempts to 
estimate the epidemiology of PID in many countries with wide 
variability. For example, the prevalence of PID was estimated 
at 5.6/100,000 in Australia and New Zealand in 2007,5) 5.38/ 
100,000 inhabitants in France in 2011,6,7) and 1.94/100,000 in 
the United Kingdom in 2011.6,7) These estimates of prevalence 
may be lower than the actuals because these numbers were drawn 
from registries.
Globally, the Jeffrey Modell Foundation has established a 
network of physician experts on PID (Jeffrey Modell Centers 
Network) and performs an annual global survey. From the last 
survey report in 2014, as of 2013, 138,847 patients were being 
followed by PID expert physicians and 77,192 patients were 
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confirmed as having PID in surveys collected from 225 centers 
in 78 countries in 6 continents.6) In 2013, there were 74.1% and 
27.9% increases in the number of patients followed and those 
with an identified PID, respectively, compared to 2011.6)
In 2017, the physicians reported a total of 187,988 patients 
with PID, with an estimated global prevalence of 2.5 per 
100,000 persons.8,9)
In Japan, a survey was conducted on PID patients who were 
alive on December 1, 2008 and those who were newly diagnosed 
and dead between December 1, 2007 and November 30, 2008. 
This study estimated the prevalence of PID as 2.3 per 100,000 
persons (Table 1).4)
In Korea, a study investigated the epidemiology of PID from 
2001 to 2005 and identified 152 patients from 23 major hos-
pitals.10) In this study, the prevalence of PID in Korea in 2005 was 
1.13 per 100,000 persons. However, these numbers may have 
been underestimated; thus, further studies are needed.
Advancement in diagnosis and management 
of PID
Certain PIDs have typical presentations, but the clinical manife-
stations among many PIDs are variable, although they are also 
similar. Therefore, taking a diagnostic approach according to 
phenotypic classification helps clinicians greatly when faced with 
potential PID.11) Samples from PID patients are often evaluated 
using flow cytometry analysis. In Korea, basic lymphocyte subset 
analysis (T, B, NK cells, and monocytes) by flow cytometry is 
relatively readily available in many referral centers, whereas tests 
such as dihydrorhodamine to screen for chronic granulomatous 
disease (CGD) are currently available only in 3 centers in the 
nation. In addition, several other functional tests are not available 
in the clinical laboratories of Korean hospitals. PID patients are 
in urgent need of a national insurance benefit for immunology 
work-ups. For example, the cost for lymphocyte subset analysis is 
not properly reimbursed, even for patients with severe combined 
immunodeficiency (SCID) or X-linked agammaglobulinemia 
(XLA), and deferred automatically in an electronic reimburse-
ment system by the national health insurance system. However, it 
is reimbursed for cancer patients who undergo hematopoietic cell 
transplantation (HCT) and follow-up tests during the post-HCT 
period. Increased awareness is warranted among physicians in the 
clinical field and officers at the national health insurance review 
agency to increase the care benefit of PID patients at the dia-
gnostic workup stage and during their disease follow-up period. 
Therefore, support and relevant health policies are need ed at the 
government level.
Since PIDs are typical examples of single-gene inborn errors of 
immunity, the genetic diagnosis is crucial for the final confirma-
tion of the disease. It is noteworthy that, according to Casanova 
et al.,12) up to 49 of the 232 monogenetic etiologies (21%) of 
human PIDs were initially reported in single patients. With the 
advancement of genetic analysis technology in the next-genera-
tion sequencing era, the cumulative number of single-gene de-
fects underlying PIDs has increased in a short period of time.13) 
However, next-generation sequencing does not analyze all of the 
unknown causes of underlying genetic mutations, and 15%–40% 
of those unknown cases are solved.14) Therefore, clinicians must 
detect clinical clues and characterize each phenotype.
Traditional management strategies of PID patients include 
immunoglobulin (Ig) replacement, HCT, and antimicrobial pro-
phylaxis. Gene therapy has been also attempted in the field. 15,16) 
With advances in genetic diagnosis and basic immunology, there 




HIRA datab) USc) EUd) Japane)
Total (estimates) 398 1,162 5,346 19,355 2,900
General population, 2019 51,833,175 329,676,200 512,600,000 125,941,289
Prevalence (per 100,000) 2.2 1.6 3.8 2.3
I. Immunodeficiencies affecting cellular and humoral immunity (SCID, CID, etc.) 11 (3) 42 (4) 513 (10) 1,445 (7) 93 (7)
II. CID with associated or syndromic features (WAS, DiGeorge, HIES, etc.) 37 (10) 43 (4) 1,076 (20) 2,693 (14) 194(16)
III. Predominantly antibody deficiencies (XLA, etc.) 143 (36) 460 (40) 2,663 (50) 10,966 (57) 501 (40)
IV. Diseases of immune dysregulation (HLH, CTLA-4, etc.) 58 (15) NA 225 (4) 753 (4) 49 (4)
V. Congenital defects of phagocyte (CGD, etc.) 104 (26) 124 (11) 638 (12) 1,689 (9) 230 (19)




95 (2) 193 (1) 15 (1)
VII. Auto-inflammatory disorders (FMF, etc.) 4 (1) NA 398 (2) 108 (9)
VIII. Complement deficiencies (aHUS, etc.) 36 (9) 26 (0.5) 946 (5) 32 (3)
IX. Phenocopies of PID 0 (0) Others: 110 272 (1) 18 (1)
Values are presented as number or number (%).
PID, primary immunodeficiency disease; IUIS, International Union of Immunological Societies; SCID, severe combined immunodeficiency; CID, combined 
immunodeficiency; WAS, Wiskott Aldrich syndrome; HIES, hyper immunoglobulin E syndrome; XLA, X-linked agammaglobulinemia; HLH, hemophagocytic 
lymphohistiocytosis; CTLA-4, hyper immunoglobulin E syndrome; CGD, chronic granulomatous disease; FMF, familial mediterranean fever; aHUS, atypical 
hemolytic uremic syndrome; NA, not available.
a)Systematic review of PID reports in Korea (2001–2018). b)Health Insurance Review and Assessment Service (HIRA) Korea (2017). c)US Immunodeficiency 
Network (USIDNET) (2019). d)European Society for Immunodeficiencies (ESID) registry (2014). e)Nationwide survey of patients with primary immunodeficiency 
diseases in Japan (2007–2008). 
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are opportunities for newer therapeutic options using targeted 
therapy at the molecular level. In 2018, the Nobel Prize was given 
to one of the researchers who worked on the CTLA-4 gene.17) 
Although much attention was given to the application of CTLA-4 
for cancer treatment, PID patients with the CTLA-4 mutation can 
also benefit from target therapy using CTLA-4 Ig treatment.18,19) 
The current Korean health insurance system was mainly designed 
to enable the reimbursement for common diseases with high 
numbers of patients such as diabetes, hypertension, or cancers. 
In more common diseases such as can cers, many advanced target 
therapies at the molecular level are being used in the clinical 
field in Korea. However, there are many hurdles for rare PID 
patients (e.g., only one patient diagnosed in Korea) who may 
need this type of special target therapy as well as reimbursement 
from the Korean government system. There should be a formal 
and easy to approach channel in Health In surance Review and 
Assessment Service (HIRA) with staff designated to manage rare 
diseases issues to ensure efficient com munication and eventually 
benefits for patients with rare diseases who also have the right 
to receive the best care possible in Korea. Therefore, there is a 
need to estimate the disease burden of PID in Korea and identify 
advanced treatment options in Korean PID patients. This is also 
achievable at the global level given the fact of the rarity of the 
diseases and PID experts constantly collaborate to provide the 
world cohort data in the literature20); Korean patient data should 
be analyzed internationally to provide evidence for a therapeutic 
approach in Korea.
The number of physicians with advanced knowledge about 
PID and proper training for managing these special groups of 
diseases is very limited in Korea; thus, many PID patients do not 
obtain a timely accurate diagnosis. Constant efforts including 
public awareness, physician education, and cross-talk with a 
government agency should be made to advance PID care in 
Korea.
The National Institutes of Health (NIH) is the largest public 
funder of biomedical research worldwide.21) NIH grants for 
PID were provided for 409 projects ($35,410,126) in the 
United States (US) in 2016 and 2017.22) Among them, 2 NIH 
grants ($697,747) were provided for the US Immunodeficiency 
Network (USIDNET) in 2016 and 2017.23) The USIDNET was 
established to advance scientific research on PID in the US.24) 
One of their main areas of focus is to assemble and maintain a 
registry of validated data from PID patients. The USIDNET 
has been continuously funded from the National Institute of 
Allergy and Infectious Diseases of the NIH since 2005. In Korea, 
one such project aiming to estimate the prevalence of PID was 
supported by a national grant from the Korea Centers for Dis-
ease Control & Prevention (KCDC), which reported the results 
in 2006.25) However, there is no continuous ongoing PID registry 
funded by a national grant in Korea.
Systematic review of PID reports in Korea
All Korean or English studies on PIDs reported in a Korean 
or international scientific journal between January 2001 and 
November 2018 were identified. The International Union of 
Immunological Societies (IUIS) PID expert committee developed 
the phenotypic classification to help clinicians diagnose PID at 
the bedside. This report represents the most current and com-
plete catalog of known PIDs.11) Thus, it serves as a reference 
for these conditions and provides a framework to help in the 
Fig. 1. Flowchart of the article selection process for this systematic review of primary 
immunodeficiencies in Korea. PID, primary immunodeficiency disease; IUIS, International 
Union of Immunological Societies.
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diagnostic approach to patients with suspected PID in a publi-
cation every 2 years. We searched the PubMed, KoreaMed, and 
Google Scholar databases for systematic reviews and checked for 
duplicates (Fig. 1). The diagnosis of PID was categorized from 
group I to group XI according to the 2017 IUIS Phenotypic 
Classification. The diagnosis of PID was divided into period 1, 
2001–2005, and period 2, 2006–2018, because a multicenter 
study estimated PID epidemiology from 2001 to 2005 in Korea.
A total of 398 PID patients were identified in 101 reports. Of 
them, 208 (27 reports) and 190 (74 reports) were in periods 
1 and 2, respectively (Fig. 1; Tables 1, 2). The most frequent 
PIDs were as follows: V. congenital defects of phagocyte b: 
functional defects (n=94, 23.6%), III. predominantly antibody 
deficiencies a: hypogammaglobulinemia (n=82, 20.6%), III. 
predominantly antibody deficiencies b: other antibody defici-
encies (n=62, 15.6%), and IV. disease of immune dysregulation 
a: hemophagocytic lymphohistiocytosis (HLH) & Epstein-Barr 
virus susceptibility (n=53, 13.3%). Among the diseases, CGD 
was the most frequently reported PID (n=86, 21.6%) (data not 
shown). No cases were reported of patients with VI. Defects in 
intrinsic and innate immunity b: Mendelian susceptibility to 
mycobacterial disease and viral infection, VIIb. auto-inflamma-
tory disorders, and IX. phenocopies of PID.
Among the 10 SCID cases, 5 (50.0%) were reported at 
Samsung Medical Center (data not shown).26,27) Among the 53 
cases of HLH, 20 (37.7%) were reported from Asan Medical 
Center. Among the 86 CGD cases, 46 (53.5%) were reported 
from Seoul National University.10,28,29) CTLA4 deficiency (n=5, 
1.0%) and familial Mediterranean fever (n=4, 1.0%) were not 
found in period 1 but were reported in period 2.
Table 2. Number of cases of primary immunodeficiencies in Korea in the literature







I. Immunodeficiencies affecting cellular and humoral immunity
(A) Severe combined immunodeficiencies (SCID) SCID 7 3 10
(B) Combined Immunodeficiencies NA 1 0 1
II. CID with associated or syndromic features
(A) Congenital thrombocytopenia, immunoosseous dysplasia, 
thymic defects with additional congenital anomalies
Wiskott Aldrich Sd, DiGeorge Sd, CHARGE Sd 8 21 29
(B) Hyper-IgE Sd (HIES), dyskeratosis congenita, defects of 
vitamin B12 and folate metabolism, anhidrotic ectoder-
modysplasia with immunodeficiency, others
HIES, Comel Neterton Sd 5 4 11
III. Predominantly antibody deficiencies
(A) Hypogammaglobulinemia X-linked agammaglobullinemia (BTK), CVID, acti-
vated phosphoinositide 3 kinase delta Sd (APDS)
56 26 82
(B) Other antibody deficiencies Selective IgA deficiency, IgG subclass deficiency 
with IgA deficiency, Isolated IgG subclass defici-
ency, Hyper IgM Sd
57 5 62
IV. Diseases of immune dysregulation
(A) HLH & EBV susceptibility HLH 0 53 53
(B) Sd with autoimmunity and others CTLA4 deficiency (ALPSV) 0 5 5
V. Congenital defects of phagocyte
(A) Number, function, or both - neutropenia Glycogen storage disease type 1b (G6PT1), HAX1 
deficiency (Kostmann Disease) (SCN3)
7 3 10
(B) Functional defects Cystic fibrosis (CFTR), CGD, LAD I 52 42 94
VI. Defects in Intrinsic and Innate immunity
(A) Bacterial and Parasitic Infections NA 0 1 1
(B) MSMD and Viral infection NA 0 0 0
VII. Auto-inflammatory disorders
(A) Recurrent inflammation, Systemic inflammation with urti-
carial rash, Others
FMF 0 4 4
(B) Sterile inflammation (skin/bone/joints), type 1 Interfero-
nopathies
NA 0 0 0
VIII. Complement deficiencies
Complement deficiencies C1 C3 C4 C5 C7 C9 def. atypical hemolytic uremic Sd 13 23 36
IX. Phenocopies of PID
Phenocopies of PID NA 0 0 0
Total 208 190 398
PID was categorized into groups I–XI according to the 2017 IUIS Phenotypic Classification.
PID, primary immunodeficiency disease; IUIS, International Union of Immunological Societies; NA, not available; CID, combined immunodeficiency; Sd, 
syndrome; CVID, common variable immunodeficiency; HLH, hemophagocytic lymphohistiocytosis; EBV, Epstein-Barr virus; CGD, chronic granulomatous 
disease; LAD I, leukocyte adhesion deficiency-1; MSMD, Mendelian susceptibility to mycobacterial disease; FMF, familial mediterranean fever. 
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In VIII. complement deficiencies, 13 cases of C7 and C9 
deficiency and atypical hemolytic uremic syndrome (aHUS) and 
23 cases of C1, C3, C4, C5, C7, and C9 deficiency and aHUS 
were defined in periods 1 and 2, respectively.
HIRA reimbursement data
The number of PID patients, treatment days, and reimbur-
sement requests as well as the healthcare costs were estimated for 
1 year in 2017 using data on the HIRA website (http://opendata.
hira.or.kr/).
A total of 1,162 outpatients and 306 inpatients were treated 
for 8,166 and 6,149 days, respectively; 124 outpatients (10.7%) 
and 49 inpatients (16.0%) were treated for functional defect 
of neutrophils (FDN), 460 (39.6%) and 177 (57.8%) for pre-
dominantly antibody deficiency (PAD), 42 (3.6%) and 5 (1.6%) 
for combined immunodeficiency (CID), 233 (20.1%) and 28 
(9.2%) for immunodeficiency associated with other major de-
fects (IDMD), 43 (3.7%) and 18 (5.9%) for common variable 
immunodeficiency (CVID), and 260 (22.4%) and 29 (9.5%) for 
other immunodeficiencies (Others), respectively (Fig. 2A, Table 
1).
Treatment was delivered for 8,166 and 6,149 days for out-
patients and inpatients, respectively: 1,249 (15.3%) and 1,357 
(22.1%) for patients with FDN, 3,175 (38.8%) and 672 (37.3%) 
in patients with PAD, 225 (2.7%) and 21 (4.5%) in patients with 
CID, 2,188 (26.8%) and 118 (21.1%) in patients with IDMD, 
496 (6.0%) and 68 (7.5%) in patients with CVID, and 855 
(10.4%) and 80 (7.5%) in patients with Others, respectively (Fig. 
2B).
Reimbursement was requested in 8,200 outpatient care 
episodes and 1,090 inpatient care episodes: 1,261 (15.4%) and 
131 (12.0%) for FDN, 3,175 (38.7%) and 672 (61.7%) for 
PAD, 225 (2.7%) and 21(1.9%) for CID, 2,188 (26.7%) and 
118 (10.8%) for IDMD, 496 (6.0%) and 68 (6.2%) for CVID, 
and 855 (10.4%) and 80 (7.3%) for Others for outpatient and 
inpatient care episodes, respectively (Fig. 2C).
Total healthcare cost (reimbursement plus patient copayment) 
was estimated as $1,024,000 for outpatient care and $2,500,000 
for inpatient care in 2017: $188,000 and $877,000 for FDN, 
$502,000 and $647,000 for PAD, $39,000 and $183,000 
for CID, $140,000 and $466,000 for IDMD, $105,000 and 
$142,000 for CVID, and $50,000 and $186,000 for Others, 
respectively (Fig. 2D).
In an outpatient care setting, patients with PAD (n=460) had 
the highest number of treatment visit days and the highest num-
ber of reimbursement requests, and spent the largest amount of 
healthcare cost (Fig. 2). In an inpatient care setting, patients with 
PAD (n=177) had the highest number of inpatient treatment 
days and highest number of reimbursement requests, while 
patients with FDN incurred the greatest healthcare costs.
The claims data of the HIRA is an important information 
source for healthcare service research in Korea.30) Despite its 
importance, there are a few limitations: specifically, these data 
may involve insufficient cases for rare diseases such as PID and 
data for a certain age group may be at lower frequency.
In the HIRA database, Korean Standard Classification of 
A B
C D
Fig. 2. Primary immunodeficiency disease (PID) patients who requested reimbursement in the HIRA Korea (2017). 
(A) Number of patients. (B) Number of treatment days. (C) Number of reimbursement requests. (D) Healthcare 
costs for PID. CID, combined immunodeficiency; CVID, common variable immunodeficiency; FDN, functional defect 
of neutrophils; Healthcare cost, reimbursement plus patient copayment; IDMD, immunodeficiency associated 
with other major defects; Others, other immunodeficiencies; PAD, predominantly antibody deficiency.
Son S, et al. Epidemiology of PIDs in Korea www.e-cep.org146
Disease Version 7 (KCD-7) codes are used. This is the Korean 
translation of the International Statistical Classification, 10th 
Revision (ICD-10) produced by the World Health Organization 
(WHO).31,32)
In the HIRA database, statistics for the following 6 main KCD-
7 codes for PID are as follows: FDN (D71), PAD (D80), CID 
(D81), IDMD (D82), CVID (D83), and Others (D84). These 
main codes have several subcategories. For example, according 
to ICD-10 (WHO version; 2016), PAD (D80) in cludes D80.0, 
hereditary hypogammaglobulinemia; D80.1, nonfamilial hypo -
gammaglobulinemia; D80.2, selective deficiency of IgA; D80.3, 
selective deficiency of IgG; D80.4, selective deficiency of IgM; 
D80.5, immunodeficiency with increased IgM; D80.6, antibody 
deficiency with near-normal immunoglobulins or with hyper im-
munoglobulinemia; D80.7, transient hypogammaglobulinemia 
of infancy; D80.8, other immunodeficiencies with predomi-
nantly antibody defects; and D80.9, immunodeficiency with pre-
dominantly antibody defects, unspecified.
CID (D81) includes D81.0, SCID with reticular dysgenesis; 
D81.1, SCID with low T- and B-cell numbers; D81.2, SCID with 
low or normal B-cell numbers; D81.3, adenosine deaminase de-
ficiency; D81.4, Nezelof syndrome; D81.5, purine nucleoside 
phosphorylase deficiency; D81.6, major histocompatibility com-
plex class I deficiency; D81.7, major histocompatibility complex 
class II deficiency; D81.8, other combined immunodeficiencies; 
and D81.9, combined immunodeficiency, unspecified. The sub-
categories above are also found and searchable in HIRA database 
statistics.
CVID (D83) includes D83.0, CVID with predominant abnor-
malities of B-cell numbers and function; D83.1, CVID with 
predominant immunoregulatory T-cell disorders; D83.2, CVID 
with autoantibodies to B- or T-cells; D83.8, other CVID; and 
D83.9, common variable immunodeficiency, unspecified.
Since about 40% of PID patients had an antibody deficiency, 
we took a closer look at the number of patients with PAD (agam-
maglobulinemia/other antibody deficiency [D80 and D80.0–
D80.9 in KCD-7 codes] and CVID [D83 and D83.0–D83.9]), 
the representative diseases for intravenous Ig replacement 
therapy (Fig. 3). The highest number of PAD patients plus CVID 
patients was observed in the 1st decade (Fig. 3A). Among them, 
XLA patients (D80.0 in KCD-7 codes) and CVID patients (D83 
and D83.0–D83.9 in KCD-7 codes) are shown in Fig. 3B. The 
highest number of these patients were aged 20–29 years (29 and 
14 patients, respectively).
Although IUIS classification is updated every 2 years, it has 
limited ability to reflect the changes in real time for PID coding to 
enable reimbursement in clinical practice. Several new dia gnoses 
are not properly coded in the reimbursement system in many 
countries. To address this issue, PID experts should make con-
tinuous efforts to both update IUIS classification and apply the 
IUIS classification to ICD codes in cooperation with government 
agencies. Education for physicians in the field should also be 
updated with new PID ICD codes.
Limitations
We searched published studies on PID in 101 peer-reviewed 
medical journals. Among them, 85 reports (84.2%) were written 
in Korean and 71 (70.3%) were case reports. This study could 
not estimate the prevalence or regional distribution of specific 
PIDs. To avoid duplicate reimbursements, the health insurance 
data for 1 year (2017) were used to estimate the PID disease 
healthcare cost burden. However, this was the first systematic 
review of all available Korean reports on PID and the first report 
on healthcare coast for PID patients in Asia.
Conclusion
This article described our systematic review of all reported 
PID cases in Korea (published in Korean or English) in which we 
attempted to estimate the number of PID patients and health-
care costs for the first time in Korea using open big data in the 
national health insurance reimbursement system. Our review 
revealed that Korean PID cases are greatly underreported in the 
A BAge (yr) Age (yr)
Fig. 3. Number of patients with primary immunodeficiency diseases needed to estimate the need for intravenous 
immunoglobulin treatment. (A) primary immunodeficiency diseases (agammaglo bulinemia/other antibody deficiency 
plus CVID). (B) XLA and CVID. Numbers on top of bars and over lines are the number of patients. CVID, common 
variable immunodeficiency; XLA, X-linked agammaglobulinemia.
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literature, and based on health insurance data, there are more 
than 1,000 PID patients in Korea. In addition, there is a definite 
need for increased awareness and education for the proper use 
of KCD-7 (the translated version of the ICD-10) for existing or 
newly discovered PIDs in the reimbursement system. Physicians 
in the field and health care policymakers should be aware of the 
disease burden of PID. To better estimate the epidemiology of 
PID and its disease burden in Korea, a national registry project is 
warranted at the government level.
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